Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Hasslinger, John; Sirviö, Seija; Berggren, Steve; Myers, Lynnea; Flygare, Oskar; Tammimies, Kristiina; Bölte, Sven (2016)
Publisher: Translational Developmental Psychiatry
Journal: Translational Developmental Psychiatry
Languages: English
Types: Article
Today, the treatment for children and adolescents with attention-deficit/hyperactivity disorder (ADHD) is predominantly pharmacological. However, not all individuals respond to medication or some may experience problematic side effects. In addition, the compliance and treatment fidelity to medication is sometimes limited; thus, effective non-pharmacological treatment options are desirable. Neurocognitive training (NCT) methods such neurofeedback (NF) and working memory (WMt) have shown efficacy treating the primary symptoms of ADHD in non-blinded trials. Still, larger, comparative, blinded, pragmatic randomized controlled trials (RCTs) are needed to ensure the efficacy and effectiveness of these methods, and to identify an optimal training variant. Furthermore, little is known about predictors of treatment response to NCTs, such as genetic variants. In this article, we present the protocol of a pragmatic RCT for three NCT methods: slow cortical potential (SCP) training and live z-score (LZS) training (two NF variants), and working memory training (WMt). These are evaluated against each other and a waiting list control/treatment as usual group. In a clinical outpatient setting, 200 children and adolescents with ADHD aged 9–17 years with common comorbidities are randomized to either one of the treatment groups or the waiting list control group (n=50/group). The treatment groups (SCP/LZS/WMt) receive a total of 25 highly frequent training sessions (5/week for 5 weeks). A comprehensive assessment comprising ADHD core symptoms, psychopathology, neuropsychology, neurophysiology, quality of life, and health-related measures are collected pre- and post-treatment and at a 6-month follow-up. Primary outcomes are blinded teacher and unblinded parent ratings and self-ratings on the Conners 3 for ADHD. We expect that participants receiving NCT will exhibit improved core ADHD symptomatology compared with waiting list controls. Moreover, we hypothesize that the type of NCT (i.e. SCP, LZS, WMt) and participant characteristics (e.g. genetic predisposition, age, IQ, gender, verbal skills, and comorbidity) will predict patterns of treatment effects on the various outcomes.Keywords: ADHD; ADD; comorbidity; attention; treatment; neurofeedback; working memory training; RCT; evidence-based; intervention(Published: 17 March 2016)Citation: Translational Developmental Psychiatry 2016, 4: 30556 - http://dx.doi.org/10.3402/tdp.v4.30556
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. Polanczyk GV, Willcutt EG, Salum GA, Kieling C, Rohde LA. ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis. Int J Epidemiol 2014; 43: 434 42.
    • 2. De Schipper E, Mahdi S, Coghill D, de Vries PJ, Gau SS-F, Granlund M, et al. Towards an ICF core set for ADHD: a worldwide expert survey on ability and disability. Eur Child Adolesc Psychiatry 2015; 24: 1509 21.
    • 3. De Schipper E, Lundequist A, Wilteus AL, Coghill D, de Vries PJ, Granlund M, et al. A comprehensive scoping review of ability and disability in ADHD using the International Classification of Functioning, Disability and Health-Children and Youth Version (ICF-CY). Eur Child Adolesc Psychiatry 2015; 24: 859 72.
    • 4. Thapar A, Cooper M, Eyre O, Langley K. Practitioner review: what have we learnt about the causes of ADHD? J Child Psychol Psychiatry 2013; 54: 3 16.
    • 5. Martin J, O'Donovan MC, Thapar A, Langley K, Williams N. The relationship between common and rare genetic variants in ADHD. Translational Psychiatry 2015; 5: 10 13.
    • 6. Hawi Z, Cummins TDR, Tong J, Johnson B, Lau R, Samarrai W, et al. The molecular genetic architecture of attention deficit hyperactivity disorder. Mol Psychiatry 2015; 20: 289 97.
    • 7. Doherty JL, Owen MJ. Genomic insights into the overlap between psychiatric disorders: implications for research and clinical practice. Genome Med 2014; 6: 29.
    • 8. Harpin VA. The effect of ADHD on the life of an individual, their family, and community from preschool to adult life. Arch Dis Child 2005; 90(Suppl 1): i2 7.
    • 9. Barkley RA. Major life activity and health outcomes associated with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2002; 63(Suppl. 12): 10 15.
    • 10. Biederman J, Petty CR, Evans M, Small J, Faraone SV. How persistent is ADHD? A controlled 10-year follow-up study of boys with ADHD. Psychiatry Res 2010; 177: 299 304.
    • 11. Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med 2006; 36: 159 65.
    • 12. Geissler J, Lesch K-P. A lifetime of attention-deficit/hyperactivity disorder: diagnostic challenges, treatment and neurobiological mechanisms. Expert Rev Neurother 2011; 10: 1467 84.
    • 13. Barkley RA, Brown TE. Unrecognized attention-deficit/hyperactivity disorder in adults presenting with other psychiatric disorders. CNS Spectr 2008; 13: 977 84.
    • 14. Sobanski E, Bru¨ ggemann D, Alm B, Kern S, Deschner M, Schubert T, et al. Psychiatric comorbidity and functional impairment in a clinically referred sample of adults with attention-deficit/hyperactivity disorder (ADHD). Eur Arch Psychiatry Clin Neurosci 2007; 257: 371 7.
    • 15. Joelsson P, Chudal R, Gyllenberg D, Kesti A-K, Hinkka-YliSaloma¨ki S, Virtanen J-P, et al. Demographic characteristics and psychiatric comorbidity of children and adolescents diagnosed with ADHD in specialized healthcare. Child Psychiatry Hum Dev 2015; Sept 23: Online.
    • 16. Swanson J, Arnold LE, Kraemer H, Hechtman L, Molina B, Hinshaw S, et al. Evidence, interpretation, and qualification from multiple reports of long-term outcomes in the Multimodal Treatment Study of children with ADHD (MTA): Part II: supporting details. J Atten Disord 2008; 12: 15 43.
    • 17. Hinshaw SP, Arnold LE. Attention-deficit hyperactivity disorder, multimodal treatment, and longitudinal outcome: evidence, paradox, and challenge. Wiley Interdiscip Rev Cogn Sci 2015; 6: 39 52.
    • 18. Molina BSG, Hinshaw SP, Swanson JM, Arnold LE, Vitiello B, Jensen PS, et al. The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. J Am Acad Child Adolesc Psychiatry 2009; 48: 484 500.
    • 19. Swanson JM, Elliott GR, Greenhill LL, Wigal T, Arnold LE, Vitiello B, et al. Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. J Am Acad Child Adolesc Psychiatry 2007; 46: 1015 27.
    • 20. Barner JC, Khoza S, Oladapo A. ADHD medication use, adherence, persistence and cost among Texas Medicaid children. Curr Med Res Opin 2011; 27(Suppl 2): 13 22.
    • 21. Safren SA, Duran P, Yovel I, Perlman CA, Sprich S. Medication adherence in psychopharmacologically treated adults with ADHD. J Atten Disord 2007; 10: 257 60.
    • 22. Hodgson K, Hutchinson AD, Denson L. Nonpharmacological treatments for ADHD: a meta-analytic review. J Atten Disord 2014; 18: 275 282.
    • 23. Sonuga-Barke EJS, Brandeis D, Cortese S, Daley D, Ferrin M, Holtmann M, et al. Nonpharmacological interventions for ADHD: systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatments. Am J Psychiatry 2013; 170: 275 89.
    • 24. Arns M, Heinrich H, Strehl U. Evaluation of neurofeedback in ADHD: the long and winding road. Biol Psychol 2014; 95: 108 15.
    • 25. Collura TF. Specifying and developing references for live Z-score neurofeedback. NeuroConnections 2014; Spring: 26 39.
    • 26. Gevensleben H, Rothenberger A, Moll GH, Heinrich H. Neurofeedback in children with ADHD: validation and challenges. Expert Rev Neurother 2012; 12: 447 60.
    • 27. Mayer K, Wyckoff SN, Strehl U. One size fits all? Slow cortical potentials neurofeedback: a review. J Atten Disord 2012; 17: 393 409.
    • 28. Meisel V, Servera M, Garcia-Banda G, Cardo E, Moreno I. Reprint of 'Neurofeedback and standard pharmacological intervention in ADHD: a randomized controlled trial with six-month follow-up.' Biol Psychol 2014; 95: 116 25.
    • 29. Steiner NJ, Frenette EC, Rene KM, Brennan RT, Perrin EC. Inschool neurofeedback training for ADHD: sustained improvements from a randomized control trial. Pediatrics 2014; 133: 483 92.
    • 30. Takahashi J, Yasumura A, Nakagawa E, Inagaki M. Changes in negative and positive EEG shifts during slow cortical potential training in children with attention-deficit/hyperactivity disorder: a preliminary investigation. Neuroreport 2014; 25: 618 24.
    • 31. Melby-Lerva˚g M, Hulme C. Is working memory training effective? A meta-analytic review. Dev Psychol 2013; 49: 270 291.
    • 32. Gevensleben H, Holl B, Albrecht B, Schlamp D, Kratz O, Studer P, et al. Neurofeedback training in children with ADHD: 6-month follow-up of a randomised controlled trial. Eur Child Adolesc Psychiatry 2010; 19: 715 24.
    • 33. Duric NS, Assmus J, Gundersen DI, Elgen IB. Neurofeedback for the treatment of children and adolescents with ADHD: a randomized and controlled clinical trial using parental reports. BMC Psychiatry 2012; 12: 107.
    • 34. Cortese S, Ferrin M, Brandeis D, Buitelaar J, Daley D, Dittmann RW, et al. Cognitive training for attention-deficit/ hyperactivity disorder: meta-analysis of clinical and neuropsychological outcomes from randomized controlled trials. J Am Acad Child Adolesc Psychiatry 2014; 54: 164 74.
    • 35. Heinrich H, Gevensleben H, Freisleder FJ, Moll GH, Rothenberger A. Training of slow cortical potentials in attentiondeficit/hyperactivity disorder: evidence for positive behavioral and neurophysiological effects. Biol Psychiatry 2004; 55: 772 5.
    • 36. Langer N, von Bastian CC, Wirz H, Oberauer K, Ja¨ncke L. The effects of working memory training on functional brain network efficiency. Cortex 2013; 49: 2424 38.
    • 37. Gevensleben H, Holl B, Albrecht B, Schlamp D, Kratz O, Studer P, et al. Distinct EEG effects related to neurofeedback training in children with ADHD: a randomized controlled trial. Int J Psychophysiol 2009; 74: 149 57.
    • 38. Wangler S, Gevensleben H, Albrecht B, Studer P, Rothenberger A, Moll GH, et al. Neurofeedback in children with ADHD: specific event-related potential findings of a randomized controlled trial. Clin Neurophysiol 2011; 122: 942 50.
    • 39. Bruxel EM, Akutagava-Martins GC, Salatino-Oliveira A, Contini V, Kieling C, Hutz MH, et al. ADHD pharmacogenetics across the life cycle: new findings and perspectives. Am J Med Genet Part B Neuropsychiatr Genet 2014; 165: 263 82.
    • 40. Lester KJ, Eley TC. Therapygenetics: using genetic markers to predict response to psychological treatment for mood and anxiety disorders. Biol Mood Anxiety Disord 2013; 3: 4.
    • 41. Uher R. The implications of gene-environment interactions in depression: will cause inform cure? Mol Psychiatry 2008; 13: 1070 8.
    • 42. Birbaumer N. Slow cortical potentials: plasticity, operant control, and behavioral effects. Neuroscience 1999; 5: 74 8.
    • 43. Collura TF, Guan J, Tarrant J, Bailey J, Starr F. EEG biofeedback case studies using live Z-score training and a normative database. J Neurother 2010; 14: 22 46.
    • 44. Conners CK. Conners. 3rd ed. North Tonawanda, NY: Multi-Health Syst; 2008.
    • 45. Gallant S, Conners CK, Rzepa S, Pitkanen J, Marocco M, Sitarenios G. Psychometric Properties of the Conners 3rd Edition. Poster presented at the annual meeting of the American Psychological Association, San Francisco; August 2007.
    • 46. Conners CK, Staff MHS, Connelly V, Campbell S, MacLean M, Barnes J. Conners' Continuous Performance Test II (CPT II V. 5). Multi-Health Syst Inc 2000; 29: 175 96.
    • 47. Toplak ME, Tannock R. Tapping and anticipation performance in attention deficit hyperactivity disorder. Percept Mot Skills 2005; 100(3 Pt 1): 659 75.
    • 48. Toplak ME, Rucklidge JJ, Hetherington R, John SCF, Tannock R. Time perception deficits in attention-deficit/ hyperactivity disorder and comorbid reading difficulties in child and adolescent samples. J Child Psychol Psychiatry. 2003; 44: 888 903.
    • 49. Wechsler D. The Wechsler intelligence scale for children fourth edition. Stockholm, Sweden: Pearson assessment; 2003. Swedish manual of the WISC-IV.
    • 50. Benson N, Hulac DM, Kranzler JH. Independent examination of the Wechsler Adult Intelligence Scale-Fourth Edition (WAIS-IV): what does the WAIS-IV measure? Psychol Assess 2010; 22: 121 30.
    • 51. Wechsler D, Kaplan E, Fein D, Kramer J, Morris R, Delis D, et al. Wechsler intelligence scale for children-fourth editionintegrated. San Antonio, TX: Harcourt; 2004.
    • 52. Nyman H. WAIS-III NI: WAIS-III som neuropsykologiskt instrument. 3rd ed. Stockholm, Sweden: Pearson assess; 2004. Swedish manual of the WASI-III NI.
    • 53. Owen AM, Downes JJ, Sahakian BJ, Polkey CE, Robbins TW. Planning and spatial working memory following frontal lobe lesions in man. Neuropsychologia 1990; 28: 1021 34.
    • 54. Gioia GA, Isquith PK, Guy SC, Kenworthy L. Behavior rating inventory of executive function. Child Neuropsychol 2000; 6: 235 8.
    • 55. Gioia GA, Isquith PK, Guy SC, Kenworthy L. Behavior rating of executive function. Lutz, FL: Psychol Assess Resour; 2000.
    • 56. Urzua A, Cortes E, Vega S, Prieto L, Tapia K. Psychometric properties of the KIDSCREEN-27 self-reported quality of life questionnaire in chilean adolescents. Ter Psicol 2009; 27: 83 92.
    • 57. Robitail S, Ravens-Sieberer U, Simeoni MC, Rajmil L, Bruil J, Power M, et al. Testing the structural and cross-cultural validity of the KIDSCREEN-27 quality of life questionnaire. Qual Life Res 2007; 16: 1335 45.
    • 58. Banaschewski T, Brandeis D, Heinrich H, Albrecht B, Brunner E, Rothenberger A. Questioning inhibitory control as the specific deficit of ADHD? Evidence from brain electrical activity. J Neural Transm 2004; 111: 841 64.
    • 59. Olvet DM, Hajcak G. The error-related negativity (ERN) and psychopathology: toward an endophenotype. Clin Psychol Rev 2008; 28: 1343 54.
    • 60. O¨ stberg M, Hagekull B, Hagelin E. Stability and prediction of parenting stress. Infant Child Dev 2007; 16: 207 23.
    • 61. Doll EJ. Parenting stress index. 2nd ed. Professional School Psychology 1989; 4: 307 12.
  • No related research data.
  • No similar publications.

Share - Bookmark

Download from

Cite this article

Collected from